Atsushi Shirahata1, Kenji Hibi2. 1. Gastroenterological Surgery, Showa University Fujigaoka Hospital, Aoba-ku, Yokohama, Japan Gastroenterological Surgery, Yokohama Asahi Chuo General Hospital, Aoba-ku, Yokohama Japan shirahataa@asahi-hp.jp. 2. Gastroenterological Surgery, Showa University Fujigaoka Hospital, Aoba-ku, Yokohama, Japan.
Abstract
AIMS: The present study aimed to examine the feasibility of detecting vimentin (VIM) methylation in the serum of patients with colorectal cancer (CRC) and to determine the effectiveness of a relatively simple, inexpensive, and non-invasive test performed in combination with the conventional carcinoembryonic antigen analysis. MATERIALS AND METHODS: VIM methylation in the serum DNA of 242 patients with CRC was measured by a quantitative methylation-specific polymerase chain reaction. RESULTS: A significantly higher positive rate was obtained for VIM methylation than for carcinoembryonic antigen or carbohydrate antigen 19-9 in stage 0, I, and II patients. The combination of all three markers yielded similar sensitivity for patients with disease of stage 0: 57.1%, I: 36.1%, II: 45.2%, and III: 55.4%, whereas the sensitivity reached 85.7% for patients with stage IV disease. CONCLUSION: VIM methylation of serum DNA may be a useful marker for the early detection of CRC. Copyright
AIMS: The present study aimed to examine the feasibility of detecting vimentin (VIM) methylation in the serum of patients with colorectal cancer (CRC) and to determine the effectiveness of a relatively simple, inexpensive, and non-invasive test performed in combination with the conventional carcinoembryonic antigen analysis. MATERIALS AND METHODS:VIM methylation in the serum DNA of 242 patients with CRC was measured by a quantitative methylation-specific polymerase chain reaction. RESULTS: A significantly higher positive rate was obtained for VIM methylation than for carcinoembryonic antigen or carbohydrate antigen 19-9 in stage 0, I, and II patients. The combination of all three markers yielded similar sensitivity for patients with disease of stage 0: 57.1%, I: 36.1%, II: 45.2%, and III: 55.4%, whereas the sensitivity reached 85.7% for patients with stage IV disease. CONCLUSION:VIM methylation of serum DNA may be a useful marker for the early detection of CRC. Copyright
Authors: Karen M Ridge; Dale Shumaker; Amélie Robert; Caroline Hookway; Vladimir I Gelfand; Paul A Janmey; Jason Lowery; Ming Guo; David A Weitz; Edward Kuczmarski; Robert D Goldman Journal: Methods Enzymol Date: 2015-12-19 Impact factor: 1.600
Authors: Maartje Massen; Kim Lommen; Kim A D Wouters; Johan Vandersmissen; Wim van Criekinge; James G Herman; Veerle Melotte; Leo J Schouten; Manon van Engeland; Kim M Smits Journal: Clin Epigenetics Date: 2022-04-27 Impact factor: 7.259
Authors: Reetta Holmila; Athena Sklias; David C Muller; Davide Degli Esposti; Paule Guilloreau; James Mckay; Suleeporn Sangrajrang; Petcharin Srivatanakul; Pierre Hainaut; Philippe Merle; Zdenko Herceg; Andre Nogueira da Costa Journal: PLoS One Date: 2017-03-23 Impact factor: 3.240